Study 5 of 186 for search of: "Fibromyalgia"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Exercise-Based Motivational Interviewing for Fibromyalgia
This study is currently recruiting participants.
Verified by Indiana University, October 2008
Sponsored by: Indiana University
Information provided by: Indiana University
ClinicalTrials.gov Identifier: NCT00573612
  Purpose

Fibromyalgia (FMS), defined as the presence of both chronic widespread pain and the finding of 11/18 tender points on examination, affects 2% of the general population. Drug therapy for FMS is largely symptomatic as there is not yet a complete understanding of the pathogenesis of the disease. In the past 17 years, supervised aerobic exercise has emerged as an important treatment modality to improve pain, aerobic capacity, function, and well-being. Individuals who are able to adhere to exercise almost always maintain the symptomatic benefits of exercise. Unfortunately, the rate of exercise adherence six months after the completion of a well-structured supervised exercise program is disappointingly low. Furthermore, although the efficacy of supervised aerobic exercise in the research setting is well documented, the applicability of such intervention in the clinic setting is doubtful. Therefore, we propose to conduct the Research to Encourage Exercise for Fibromyalgia (REEF), a randomized attention-controlled trial whose primary aim is to evaluate the efficacy of telephone-delivered motivational interviewing (MI) to encourage exercise, in improving exercise adherence and self-report physical function (co-primary outcome measures) for FMS patients. REEF will enroll 200 FMS patients, randomizing them to either the MI group or the attention-control (AC) group. Participants from each group will receive a total of 6 telephone calls within a 12-week period. Prior to the phone calls, participants from both groups will receive an individualized exercise prescription and 2 supervised exercise training sessions to get them started on an exercise program. All subjects will undergo comprehensive outcome assessment at baseline, week 12, week 24, and week 36. The secondary aim of this proposal is to determine the mediators between MI and improvement in self-report physical function. The proposed research is significant because our focus is the promotion of adherence to an exercise program, of adequate intensity, in order to maximize functioning and well-being for patients with FMS. The use of a predominantly home-based exercise program and telephone-delivered MI by a trained licensed practice nurse (LPN) could potentially make the proposed intervention more accessible to the greater majority of FMS patients. Furthermore, if proven efficacious, MI could readily be applied to other chronically painful conditions (e.g. chronic back pain).


Condition Intervention
Fibromyalgia
Behavioral: Attention Control Counseling
Behavioral: Motivational Interviewing

MedlinePlus related topics: Exercise and Physical Fitness Fibromyalgia
U.S. FDA Resources
Study Type: Interventional
Study Design: Supportive Care, Randomized, Single Blind (Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Exercise-Based Motivational Interviewing for Fibromyalgia

Further study details as provided by Indiana University:

Primary Outcome Measures:
  • Measure the effects of exercise-based MI intervention improving exercise adherence. [ Time Frame: This is a five year study, each subject will participate in a 9-month study sequence ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the effects of exercise-based MI intervention in pain severity and to determine between exercise-based MI intervention and the adherence. [ Time Frame: This is a five year study, each subject will participate in a 9-month study sequence ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: December 2007
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Placebo Comparator
Telephone Call for the Attention Control Group Each AC call will follow the same format as the MI call. During the AC call, study subjects will receive health information on important topics relevant to their illness. Specifically, there will be one topic during each phone call that includes the following: (a) overview of FMS, (b) pain, (c) fatigue (d) sleep, (e) stress, and (f) living well with FMS. The AC calls will be an avenue to transfer relevant health information from the RA to the study subject. The scheduled topics during each contact will give the call face validity (i.e., establish a credible pretense for the contact) while being neutral with respect to encouragement of exercise.
Behavioral: Attention Control Counseling
Subjects will receive educational-based telephone counseling regarding fibromyalgia.
2: Active Comparator
Telephone-delivered Motivational Interviewing Participants will receive 6 telephone calls throughout the study. Harland et al reported that the most effective intervention for promoting exercise in the primary care setting was the most intensive treatment arm that included six MI sessions (208). Importantly, in our pilot study, participants who completed 5 to 6 phone calls achieved greater symptomatic benefits than participants who had ≤ 4 phone calls. The phone calls will be scheduled at week 3, 4, 6, 8, 10 and 12 of the study. Telephone sessions may run for 30 minutes on the average
Behavioral: Motivational Interviewing
Subjects will receive Motivational Interviewing telephone counseling.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. American College of Rheumatology (ACR) classification criteria for FMS(203)
  2. Has been on stable doses of FMS medications (i.e., cyclobenzaprine, tramadol, gabapentin, pregabalin, venlafaxine, duloxetine, pramipexole, tricyclic anti-depressant, selective serotonin reuptake inhibitor) for at least 4 weeks and willing to limit the introduction of new medications for FMS symptoms
  3. Age between 18-65 years old. Because the prevalence of sub-clinical coronary artery disease increases with older age, we are excluding those who are ≥ 66 years old

Exclusion Criteria:

  1. FIQ-PI score < 2
  2. BPI-PS <4
  3. Known cardiovascular disease, including congestive heart failure; previous episodes of angina pectoris; previous myocardial infarction; or previous revascularization procedure
  4. Moderate-severe chronic obstructive pulmonary disease, including asthma
  5. Uncontrolled hypertension
  6. Orthopedic or musculoskeletal conditions that would prohibit moderate-intensity exercise
  7. Active suicidal ideation
  8. Planned elective surgery during the study period
  9. Ongoing unresolved disability claims
  10. Other major rheumatic conditions (i.e. rheumatoid arthritis, systemic lupus erythematosus, scleroderma and other connective tissue disease)
  11. Use of medications that may affect chronotropic response to exercise, i.e. beta-blocker or calcium channel blocker
  12. Pregnancy
  13. Schizophrenia or other psychosis
  14. Exercising 3 days a week or more. The US Surgeon General considers a physically active person as somebody who does at least 3 times a week of moderate to vigorous level of exercise(204). Thus, we are excluding the already physically active individuals from the study. In the pilot study, only 4% (2 out of 50) of the potential participants were excluded due to being physically active.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00573612

Contacts
Contact: Janna K Hilligoss, LPN, CCRC 317-278-3971 fibrofit@iupui.edu
Contact: Amelia Lengerich, BA 317-274-0670 mlengeri@iupui.edu

Locations
United States, Indiana
National Institute of Fitness of Sports, IUPUI Campus Recruiting
Indianapolis, Indiana, United States, 46202
Principal Investigator: Dennis C Ang, MD            
Sponsors and Collaborators
Indiana University
Investigators
Principal Investigator: Dennis C. Ang, MD Indiana University
  More Information

Responsible Party: Indiana University ( Dr. Dennis Ang )
Study ID Numbers: IRB 0708-62, RO1 AR054324
Study First Received: December 12, 2007
Last Updated: October 30, 2008
ClinicalTrials.gov Identifier: NCT00573612  
Health Authority: United States: Institutional Review Board

Keywords provided by Indiana University:
Fibromyalgia
Fibromyalgia patients

Study placed in the following topic categories:
Muscular Diseases
Neuromuscular Diseases
Musculoskeletal Diseases
Myofascial Pain Syndromes
Fibromyalgia
Pain
Rheumatic Diseases

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009